Inventiva (NASDAQ:IVA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Inventiva (NASDAQ:IVA) in a report issued on Thursday,Benzinga reports. HC Wainwright currently has a $13.00 price target on the stock.

A number of other equities analysts have also weighed in on IVA. UBS Group initiated coverage on Inventiva in a research note on Tuesday, November 12th. They set a “neutral” rating and a $3.00 price objective for the company. Stifel Nicolaus reduced their price target on Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, November 22nd.

Inventiva Trading Up 7.9 %

NASDAQ:IVA opened at $2.48 on Thursday. The company’s fifty day moving average price is $2.36 and its 200-day moving average price is $2.35. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.50.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.